89 related articles for article (PubMed ID: 17188539)
1. Cellular and tissue distribution of intravenously administered agalsidase alfa.
Murray GJ; Anver MR; Kennedy MA; Quirk JM; Schiffmann R
Mol Genet Metab; 2007 Mar; 90(3):307-12. PubMed ID: 17188539
[TBL] [Abstract][Full Text] [Related]
2. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
3. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.
Ioannou YA; Zeidner KM; Gordon RE; Desnick RJ
Am J Hum Genet; 2001 Jan; 68(1):14-25. PubMed ID: 11115376
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase alfa and kidney dysfunction in Fabry disease.
West M; Nicholls K; Mehta A; Clarke JT; Steiner R; Beck M; Barshop BA; Rhead W; Mensah R; Ries M; Schiffmann R
J Am Soc Nephrol; 2009 May; 20(5):1132-9. PubMed ID: 19357250
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease.
Garman RD; Munroe K; Richards SM
Clin Exp Immunol; 2004 Sep; 137(3):496-502. PubMed ID: 15320898
[TBL] [Abstract][Full Text] [Related]
6. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease.
Germain DP; Linhart A
Front Genet; 2024; 15():1395287. PubMed ID: 38680424
[TBL] [Abstract][Full Text] [Related]
7. Reproduction in Animal Models of Lysosomal Storage Diseases: A Scoping Review.
Vuolo D; Do Nascimento CC; D'Almeida V
Front Mol Biosci; 2021; 8():773384. PubMed ID: 34869599
[No Abstract] [Full Text] [Related]
8. Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice.
Wu YS; Khanna R; Schmith V; Lun Y; Shen JS; Garcia A; Dungan L; Perry A; Martin L; Tsai PC; Hamler R; Das AM; Schiffmann R; Johnson FK
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1075-1088. PubMed ID: 33876577
[TBL] [Abstract][Full Text] [Related]
9. The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells.
Tian W; Ye Z; Wang S; Schulz MA; Van Coillie J; Sun L; Chen YH; Narimatsu Y; Hansen L; Kristensen C; Mandel U; Bennett EP; Jabbarzadeh-Tabrizi S; Schiffmann R; Shen JS; Vakhrushev SY; Clausen H; Yang Z
Nat Commun; 2019 Apr; 10(1):1785. PubMed ID: 31040271
[TBL] [Abstract][Full Text] [Related]
10. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
11. Locally anchoring enzymes to tissues via extracellular glycan recognition.
Farhadi SA; Bracho-Sanchez E; Fettis MM; Seroski DT; Freeman SL; Restuccia A; Keselowsky BG; Hudalla GA
Nat Commun; 2018 Nov; 9(1):4943. PubMed ID: 30467349
[TBL] [Abstract][Full Text] [Related]
12. Enzymes as Immunotherapeutics.
Farhadi SA; Bracho-Sanchez E; Freeman SL; Keselowsky BG; Hudalla GA
Bioconjug Chem; 2018 Mar; 29(3):649-656. PubMed ID: 29285931
[TBL] [Abstract][Full Text] [Related]
13. Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice.
Shen JS; Busch A; Day TS; Meng XL; Yu CI; Dabrowska-Schlepp P; Fode B; Niederkrüger H; Forni S; Chen S; Schiffmann R; Frischmuth T; Schaaf A
J Inherit Metab Dis; 2016 Mar; 39(2):293-303. PubMed ID: 26310963
[TBL] [Abstract][Full Text] [Related]
14. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
15. Carpal tunnel syndrome in fabry disease.
Ghali J; Murugasu A; Day T; Nicholls K
JIMD Rep; 2012; 2():17-23. PubMed ID: 23430848
[TBL] [Abstract][Full Text] [Related]
16. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
17. Functional studies of new GLA gene mutations leading to conformational Fabry disease.
Filoni C; Caciotti A; Carraresi L; Cavicchi C; Parini R; Antuzzi D; Zampetti A; Feriozzi S; Poisetti P; Garman SC; Guerrini R; Zammarchi E; Donati MA; Morrone A
Biochim Biophys Acta; 2010 Feb; 1802(2):247-52. PubMed ID: 19941952
[TBL] [Abstract][Full Text] [Related]
18. Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.
Pastores GM
Biologics; 2007 Sep; 1(3):291-300. PubMed ID: 19707338
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
Shin SH; Kluepfel-Stahl S; Cooney AM; Kaneski CR; Quirk JM; Schiffmann R; Brady RO; Murray GJ
Pharmacogenet Genomics; 2008 Sep; 18(9):773-80. PubMed ID: 18698230
[TBL] [Abstract][Full Text] [Related]
20. Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.
Keslová-Veselíková J; Hůlková H; Dobrovolný R; Asfaw B; Poupetová H; Berná L; Sikora J; Golán L; Ledvinová J; Elleder M
Virchows Arch; 2008 Jun; 452(6):651-65. PubMed ID: 18351385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
